DRUG PRODUCT REGISTRATION IN SEMI-REGULATED MARKET

  • Jitendra Kumar Badjatya Department of Pharmacy, JJT University, Chudela, Jhunjhunu, Rajasthan. India
  • Ramesh Bodla (Department of Pharmaceutical Chemistry, DIPSAR New Delhi, India)
DOI https://doi.org/10.22270/ijdra.v1i2.3

Abstract

There found a diversity of regulatory requirement in Semi regulated market. This region consists of mainly the
countries from Asia pacific, Latin America, Eastern Europe, Africa and Gulf countries. Countries from Asia pacific
and Gulf have somewhat harmonized their regulatory environment through The Association of Southeast Asian
Nations (ASEAN) and Gulf Co-operation Council (GCC) organizations, ROW countries yet to be harmonized
regulations in their respective regions.
The urgent requirement to rationalize & harmonize regulation was required by instance of rising cost of health care,
research & development and to meet the public requirement for safe and efficacious treatments to patient in need.
ICH committee has given priority to harmonize the format of reporting data for quality, safety and Efficacy in the
application dossier.
The commercial significance of ROW markets is increasing globally. It is crucial that pharmaceutical companies keep
up-to-date with the latest regulatory developments to ensure their place on the ROW market.
This paper favors the regulatory processes for gaining marketing authorization in ROW countries in terms of
technical data requirement for the dossier.
 

Keywords: DRA, ASEAN, GCC, BMR, ROW, CIS, DMF, TSE/BSE, ICH, FP.

Downloads

Download data is not yet available.

References

1. WHO guidelines for stability testing of active
substances and pharmaceutical products
[Internet].[cited 2013 Jan] Available from:
http://apps.who.int/medicinedocs/documents/s19133en/
s19133en.pdf
2. Quality Guidelines – ICH Guidelines
[Internet].[cited 2013 March] Available from:
http://www.ich.org/products/guidelines/quality/article/q
uality-guidelines.html
3. Regulatory_affairs [Internet].[cited 2013 Jan]
Available from http://en.wikipedia.org/wiki
/Regulatory_affairs.
4. European Medicines Agency (EMA)Scientific
Guideline [Internet].[cited 2013 Jan] Available from
http://www.emea.europa.eu/docs /en_GB/document_
library/Scientific_guideline/2009/09/WC500002651.pd
f
5. Stability testing of Pharmaceutical Products in a
Global Enviornment [Internet].[cited 2013 May]
Available from http://www.who.int/medicines/
areas/quality_safety/quality_assurance/RAJ2006WHO
Stability.pdf
Statistics
3711 Views | 3036 Downloads
How to Cite
Badjatya, J. K., and R. Bodla. “DRUG PRODUCT REGISTRATION IN SEMI-REGULATED MARKET”. International Journal of Drug Regulatory Affairs, Vol. 1, no. 2, Feb. 2018, pp. 1-6, doi:10.22270/ijdra.v1i2.3.
Issue
Vol 1 No 2 (2013): VOLUME 1, ISSUE 2, 2013
Section
Review

The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.

I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.

Download link for COPYRIGHT FORM